Can US growth and the Cenexi turnaround improve margins?

GLAND Gland Pharma is scheduled to announce its Q2 FY27 results today, November 6. Previous quarter snapshot: Q1 FY27 revenue: ₹1,800 crore, up 19.5% YoY. Q1 FY27 net profit: ₹317 crore, up 47.4% YoY. US revenue: ₹981 crore, up 32% YoY. Consolidated EBITDA margin: approximately 27%. These are Q1 reported figures, not Q2 estimates. Why this matters: Gland Pharma's injectable business has opportunities in the US market, but investors will also be watching the integration and profitability improvement of its European subsidiary, Cenexi. What to monitor next: US revenue growth Consolidated EBITDA margins Cenexi revenue and profitability New product launches and USFDA approvals Management's FY27 growth guidance My analytical view: The key question is whether strong US business momentum can translate into sustainable consolidated margin improvement. Cenexi's recovery will also be important for the longer-term earnings outlook. Disclosure: State your actual holding or interest, if any, before publishing. SEBI RA Disclaimer: Umang Rajesh Bhutada is a SEBI-registered Research Analyst (INH000023001). This content is for educational and informational purposes only and is not investment advice. Securities investments are subject to market risks. Please consult a qualified financial professional before making investment decisions.